Anti-Centromere Antibodies (ACA)

The antibody is one of the more specific findings in autoimmune blood work. The Frontiers in Immunology review puts its specificity for systemic sclerosis in the range of 95 to 98%, which means a clear positive is hard to explain away as background noise. It appears in roughly 20 to 38% of all systemic sclerosis patients, and that group is heavily concentrated in one subtype.

That subtype is limited cutaneous systemic sclerosis, the form once called CREST. MedlinePlus notes the antibody shows up in about 60 to 80% of people with the limited cutaneous form. The skin involvement here stays mostly on the hands, forearms, face, and feet, and the disease tends to build slowly. People describe puffy, swollen fingers early on, then skin on the fingers that feels tight or shiny, tiny red spots on the face and hands, calcium lumps under the skin, and reflux or trouble swallowing as the years pass.

The forward-looking part is what the antibody does before any of that. In someone whose only complaint so far is Raynaud's attacks, a positive anti-centromere shifts the odds toward developing systemic sclerosis later. It does not make the diagnosis today. It tells a rheumatologist this is a person to follow rather than reassure and discharge.

Because the antibody is not exclusive to scleroderma, a positive result is interpreted alongside symptoms and the rest of the autoimmune workup. The presence of anti-centromere narrows the field. It does not close the case by itself.

Here is where the trailer names which feature is coming. Different scleroderma antibodies forecast different complications, and they tend to sort themselves into different people. Anti-Scl-70 (anti-topoisomerase I) is the marker of diffuse disease and is associated with lung fibrosis, the scarring of lung tissue. Anti-centromere is the other story. The two rarely travel together: in a 4,687-patient EUSTAR analysis, only about 0.6% of patients carried both.

Anti-centromere positivity instead carries a higher risk of pulmonary arterial hypertension, raised pressure in the arteries of the lungs, and is negatively associated with heart and kidney involvement. So the organ to watch is the lungs' blood vessels, not the lung tissue that anti-Scl-70 puts at risk. Orphanet describes pulmonary arterial hypertension as a late complication in roughly 10% of limited cutaneous systemic sclerosis and a leading cause of death in the disease. The American College of Rheumatology frames it as serious but treatable, which is the reason a positive result tends to put the lungs and the lung-artery pressure on a clinician's monitoring list.

There is a more hopeful side to the forecast. The limited cutaneous form anti-centromere points to carries a better outlook than diffuse disease. Research on survival across subtypes reports roughly 78.6% ten-year survival for the limited form against about 69.7% for the diffuse form. The antibody, in other words, often signals the less aggressive movie.

A single anti-centromere result is a snapshot. Its real value comes from being read in context: against your symptoms, against the rest of the autoimmune workup, and against time. Knowing how a flagged value fits the larger pattern matters more than the index number alone, and understanding what a reference range means helps explain why a low positive still counts as present.

If you are working through a positive ANA and trying to see how the pieces fit, the guide to reading an autoimmune panel walks through how markers like this one, rheumatoid factor, and anti-Jo-1 get sorted into different stories. For anti-centromere, the story is unusual in that the test can run ahead of the symptoms. The trailer screens first. Whether the feature ever opens, and how quickly, is what the watching is for.